Dr. Mark Besancon is a practicing veterinarian, consultant, and founder of DrMark.Vet, committed to enhancing canine care through education and clinical collaboration. In this blog, he shares a personal perspective on how ongoing casework and peer collaboration have influenced his evolving approach to regenerative therapies. He reflects on the role AlphaFlo® now plays in his clinical decision-making and shares observations from everyday practice.
From Supplement to Starting Point:
How AlphaFlo® Transformed My Clinical Approach
In my previous article, I shared my journey to becoming a Key Opinion Leader (KOL) for AlphaFlo® – a biologic that has fundamentally changed the way I approach patient care.
If you missed it, you can read it here: A Veterinarian’s Journey to Adopting AlphaFlo® in Clinical Practice.
What I didn’t expect when stepping into this role was how much I would grow as a clinician. Every conversation with colleagues, every patient treated, and every case-review session has expanded my understanding of regenerative medicine. The ability to deliver the biologically active proteins our patients need to heal themselves is, simply put, remarkable – and the results continue to surprise me.
There are cases I once believed had little hope of recovery – and AlphaFlo® proved me wrong.
So… What Exactly Is Amniotic Tissue Allograft?
In simple terms, it’s a concentrated matrix of biologically active proteins sourced from the acellular amniotic layer of the placenta. Through a rigorous process, the tissue is purified, micronized, and cryopreserved, ultimately producing a consistent solution containing over 1,900 biologically active proteins that help support tissue healing and regeneration.
These proteins don’t replace the body’s healing process – they fuel it.
As a KOL, I regularly speak with veterinarians across the country – general practitioners, integrative/holistic practitioners, and specialists. We discuss case strategies, routes of administration, expected outcomes, and lessons learned. Regardless of practice philosophy, clinicians are integrating AlphaFlo® because it supports healing across a wide range of conditions.
Common everyday conditions:
• Allergies
• Dental disease
• Gastrointestinal disease
• Arthritis
• Urinary issues
• Corneal ulcers
More complex medical challenges:
• Orthopedic conditions
• Neurologic conditions
• Autoimmune diseases
• Systemic diseases
• Neoplasia
• Retinal disorders
Every case – routine or advanced – continues to reinforce that regenerative medicine has a meaningful place in veterinary patient care.
I used to consider regenerative therapy as a supplemental option – something to add only after exhausting traditional approaches.
Today, the paradigm has flipped.
I now start with AlphaFlo® as a foundational biologic and layer traditional therapies as needed. The shift wasn’t philosophical; it was clinical. As outcomes improved and cases responded more quickly and more completely, it became clear that this tool belongs at the front of the treatment plan, not in the “extras” column.
The greatest honor in this journey has been working alongside colleagues who are curious, innovative, and dedicated to improving patient outcomes. Every success story – from improved mobility to restored comfort in chronic disease patients – fuels the momentum.
Whether your practice is conventional, integrative, or specialty-based, AlphaFlo® has a place in your therapeutic toolbox. And I don’t say that lightly – I say that because I’ve witnessed it.
And I’m just getting started…